Advaxis, Inc. (OTCMKTS:ADXS) Short Interest Down 27.5% in September
Advaxis, Inc. (OTCMKTS:ADXS) Short Interest Down 27.5% in September
Advaxis, Inc, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of proprietary Listeria monocytogenes (Lm) technology antigen delivery products in the United States. The company is developing ADXS-PSA, which is in Phase 2 clinical trials for the treatment of metastatic prostate cancer; ADXS-503 that is in Phase 1/2 clinical trials for the treatment of non-small cell lung cancer; and ADXS-504 for the treatment of prostate cancer.Advaxis, Inc. (OTCMKTS:ADXS – Get Rating) saw a large decrease in short interest in September. As of September 15th, there was short interest totalling 2,900 shares, a decrease of 27.5% from the August 31st total of 4,000 shares. Based on an average daily volume of 6,000 shares, the days-to-cover ratio is currently 0.5 days.
9月份，Advaxis, Inc.（OTCMKTS: ADXS — 獲取評級）的空頭利率大幅下降。截至9月15日，空頭利息共計2900股，較8月31日的4,000股減少了27.5％。根據6,000股的平均每日成交量，目前的發行天數比率爲0.5天。
Advaxis Stock Up 2.3 %
Advaxis 股票上漲2.3％
ADXS opened at $2.21 on Friday. Advaxis has a fifty-two week low of $1.02 and a fifty-two week high of $44.80. The firm has a market cap of $4.00 million, a price-to-earnings ratio of -22.05 and a beta of 2.07. The stock has a 50-day simple moving average of $3.23.
週五，ADXS開盤價爲2.21美元。Advaxis創下五十二週低點1.02美元，五十二週高點爲44.80美元。該公司的市值爲400萬美元，市盈率爲-22.05，beta爲2.07。該股的50天簡單移動平均線爲3.23美元。
Analyst Ratings Changes
分析師評級變化
Separately, StockNews.com initiated coverage on shares of Advaxis in a research report on Monday, August 22nd. They set a "sell" rating on the stock.
另外，StockNews.com在8月22日星期一的一份研究報告中開始報道Advaxis的股票。他們對該股設定了 “賣出” 評級。
About Advaxis
關於 ADVAXIS
Advaxis, Inc, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of proprietary Listeria monocytogenes (Lm) technology antigen delivery products in the United States. The company is developing ADXS-PSA, which is in Phase 2 clinical trials for the treatment of metastatic prostate cancer; ADXS-503 that is in Phase 1/2 clinical trials for the treatment of non-small cell lung cancer; and ADXS-504 for the treatment of prostate cancer.
Advaxis, Inc是一家處於臨床階段的生物技術公司，專注於在美國發現、開發和商業化專有的單核細胞增生李斯特菌（Lm）技術抗原遞送產品。該公司正在開發用於治療轉移性前列腺癌的ADXS-PSA；正在開發治療轉移性前列腺癌的第二階段臨床試驗；ADXS-503 正在進行治療非小細胞肺癌的1/2期臨床試驗；以及用於治療前列腺癌的 ADXS-504。
Recommended Stories
推薦故事
- Get a free copy of the StockNews.com research report on Advaxis (ADXS)
- Humana Proves Vertically Integrated Healthcare Works
- What Cintas Can Teach Investors About This Bear Market?
- 2 Casino Stocks Worth Taking a Look At
- This Small-Cap Healthcare Name Is Outperforming Its Index
- Blackberry Stock Declines As Results Come In Lukewarm Once Again
- 免費獲取 Advaxis (ADXS) 上的 StockNews.com 研究報告的副本
- Humana 證明垂直整合的醫療保健行之有效
- 關於這個熊市，辛塔斯能教給投資者甚麼？
- 2 只值得一看的賭場股票
- 這家小型醫療保健公司的表現優於其指數
- 隨着業績再次出爐，黑莓股價下跌
Receive News & Ratings for Advaxis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Advaxis and related companies with MarketBeat.com's FREE daily email newsletter.
接收 Advaxis 每日新聞和評級 -在下面輸入您的電子郵件地址，即可通過Marketbeat.com的免費每日電子郵件時事通訊接收Advaxis和相關公司的最新新聞和分析師評級的簡明每日摘要。